- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Italian PACS firm plans entry into U.S.
Italian PACS firm plans entry into U.S.An Italian PACS developer has filed a 510(k) application with the Food and Drug Administration in preparation for U.S. sales of its product line. The company, Program S.r.l. of Vicenza, has also signed a
Italian PACS firm plans entry into U.S.
An Italian PACS developer has filed a 510(k) application with the Food and Drug Administration in preparation for U.S. sales of its product line. The company, Program S.r.l. of Vicenza, has also signed a letter of intent with a U.S. company for exclusive distribution rights in the U.S. and Canada.
Program was established in 1994 and has a dominant share of the PACS market in Italy, where it installed its first beta site three years ago. Program's products are also marketed in Germany, Switzerland, and Austria, and the company recently signed on Duncan Hynd Associates (DHA) for distribution in the U.K. and Ireland.
Program's MedStation PACS line is based on the Windows NT operating system, and company representatives compare it to offerings from Rogan, Applicare, Cemax-Icon, and CompuRad. One differentiating feature of MedStation, however, is its ability to conduct maximum intensity projection (MIP) image-fusion display, in which an image from one modality, such as CT, is overlaid on that from another, like MRI. The technique is often used for applications such as radiation treatment planning.
In addition to filing the 510(k) application for MedStation last month, Program is in discussions with Service Support Group (SSG) of Seattle for exclusive North American distribution rights. SSG is an equipment service and asset management company that is interested in entering the market for healthcare information technology. Program hopes to have clearance for MedStation by this year's Radiological Society of North America meeting.
Can AI Bolster Breast Cancer Detection in DBT Screening?
January 16th 2025In sequential breast cancer screening with digital breast tomosynthesis (DBT), true positive examinations had more than double the AI case score of true negative examinations and the highest positive AI score changes from previous exams, according to new research.
CT Study Reveals Key Indicators for Angiolymphatic Invasion in Non-Small Cell Lung Cancer
January 15th 2025In computed tomography (CT) scans for patients with solid non-small cell lung cancer (NSCLC) < 30 mm, emerging research suggests the lollipop sign is associated with a greater than fourfold likelihood of angiolymphatic invasion.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
